Recent investigations on retatrutide, a dual agonist for glucagon-like peptide-1 and GIP, demonstrate significant outcomes in managing excess body fat and type 2 glucose intolerance. Early data from clinical assessments point to substantial reductions in body mass and bettered glucose control. Ongoing research is centered on long-term harmlessness